In 2015, Lamberto Andreotti earned $4.55M in total compensation at Bristol-Myers Squibb, including $1.05M salary and $2.69M bonus. Most recently acquired 57 shares in Jun 2017. Currently holds stock worth $51.67M. Has donated $2.34M in stock to charitable causes. Led Bristol-Myers Squibb as CEO for 5 years.
Compensation History
Annual executive compensation data for Lamberto Andreotti, including salary, bonuses, and stock awards.
Year
2015
Total Compensation
$4.55M
Salary
$1.05M
Bonus
$2.69M
Other
$800.00K
Salary
$1.05MBoard Justification
The compensation program is designed to align executives' interests with those of shareholders, emphasizing performance-based pay.
Bonus
$2.69MBoard Justification
The annual incentive award was pro-rated through his retirement date effective August 3, 2015.
Other Compensation
$800.00KBoard Justification
This includes the full distribution of his Benefit Equalization Plan benefit in the gross amount of $6,230,078, effective March 1, 2016, and interest of $54,714 for the six-month delay.
Restricted Stock
Board Justification
Mr. Andreotti did not receive any PSU awards for his service as CEO in 2015.
Performance Metrics
The performance metrics for the annual incentive plan included non-GAAP diluted EPS, total revenues, and pipeline performance.
Lamberto Andreotti
Ex-CEO of Bristol-Myers Squibb
Education
Not specified
Field of Expertise
Business & Management
Sector of Economy
Healthcare
Born
April 5, 1951 - 74 years ago
CEO of Bristol-Myers Squibb for
5 years 0 months (May 2010 - May 2015)
Previous Experience
Various senior roles within Bristol-Myers Squibb
Other Bristol-Myers Squibb CEOs
Holdings
Track Lamberto Andreotti's stock holdings and portfolio value over time.
Total Stock Sold
$101.66M
$101.66M
1,709,541 BMY shares
What if they kept their stock?
If Lamberto Andreotti didn't sell their stock, today they would have:
Extra BMY1,709,541 shares worth $88.81M.
This is -12.64% and $12.85M less than what they got when they sold the stock.
Charitable Transactions
45,000 shares
BMY
Recent Charitable Transactions
45,000 shares
BMY
Nov 19, 2015
Charity
Insider Trading
Lamberto Andreotti's recent stock transactions, purchases, and sales filed with the SEC.
$4.66K
DD at $82.14/share
Jun 12, 2017
Received
1,920 shares
DD
May 24, 2017
Received
$1.81M
BMY at $53.26/share
Apr 6, 2017
Sale
$24.96K
BMY at $54.38/share
Mar 31, 2017
Received
$1.91M
BMY at $56.17/share
Mar 27, 2017
Sale
$4.64K
DD at $80.42/share
Mar 14, 2017
Received
$24.95K
BMY at $58.44/share
Dec 31, 2016
Received
$4.62K
DD at $73.71/share
Dec 14, 2016
Received
$24.96K
BMY at $53.92/share
Sep 30, 2016
Received
$4.59K
DD at $68.17/share
Sep 12, 2016
Received
Rivals
Compare Lamberto Andreotti with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Daniel O'Day
CEO of Gilead Sciences
2024 Compensation
Stock
$18.79M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Total Holdings
$23.48M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
2022 Compensation
Stock
$10.64M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Total Holdings
$50.74M